Overview

Safety and Efficacy of AEG33773 Versus Placebo in Patients With Painful Diabetic Peripheral Neuropathy

Status:
Completed
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
Two Phase 1 studies have been conducted with AEG33773 and available safety and tolerability data from these studies support further clinical development of AEG33773. The current study is proposed as a proof-of-concept study to assess the potential analgesic efficacy of AEG33773 to reduce pain associated with chronic Diabetic Peripheral Neuropathy.
Phase:
Phase 2
Details
Lead Sponsor:
Aegera Therapeutics